A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Hummingbird Bioscience
Novartis
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Verastem, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Novartis
Revolution Medicines, Inc.
National Cancer Institute (NCI)
University of Chicago
Revolution Medicines, Inc.
Erasca, Inc.
Allist Pharmaceuticals, Inc.
D3 Bio (Wuxi) Co., Ltd
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
FBD Biologics Limited
Sanofi